No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
TNDM240621C65000
- 0.06
- +0.01+20.00%
15min DelayClose Jun 14 11:48 ET
0.06High0.06Low
0.06Open0.05Pre Close3 Volume1.72K Open Interest65.00Strike Price18.00Turnover136.22%IV43.53%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier5DDays to Expiry0.06Extrinsic Value100Contract SizeAmericanOptions Type0.0220Delta0.0068Gamma755.50Leverage Ratio-0.0300Theta0.0001Rho16.63Eff Leverage0.0030Vega
Intraday
- 5D
- 1D
News
Tandem Diabetes Care (NASDAQ:TNDM) Shareholders Are Still up 85% Over 1 Year Despite Pulling Back 5.5% in the Past Week
If you want to compound wealth in the stock market, you can do so by buying an index fund. But if you pick the right individual stocks, you could make more than that. For example, the Tandem Diabete
Oppenheimer Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Raises Target Price to $58
Oppenheimer analyst Steven Lichtman maintains $Tandem Diabetes Care(TNDM.US)$ with a buy rating, and adjusts the target price from $55 to $58.According to TipRanks data, the analyst has a success rate
Express News | Tandem Diabetes Care, Inc. : Oppenheimer Raises Target Price to $58 From $47
AMD To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Susquehanna
Tandem Diabetes Care Is Maintained at Outperform by Oppenheimer
Tandem Diabetes Care Is Maintained at Outperform by Oppenheimer
Oppenheimer Maintains Outperform on Tandem Diabetes Care, Raises Price Target to $58
Oppenheimer analyst Steven Lichtman maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Outperform and raises the price target from $47 to $58.
Comments
$Tandem Diabetes Care(TNDM.US$
Just check call options. they are expensive
However, stock price moves only 5-10% with no news. Something is going on behind the scene?!
Just check call options. they are expensive
However, stock price moves only 5-10% with no news. Something is going on behind the scene?!
1
Despite losses and negative cash flow, the company's US$178.2m balance sheet allows for at least two years of growth spending. However, the stock is seen as risky due to these financial conditions.
1
Tandem Diabetes Care's share price rise sparks hope, but turnarounds can be risky. The gap between revenue and share price growth could warrant further investigation. Last year's performance suggests unresolved issues, as it underperformed the annualised 10% loss over the past five years.
The stock is undervalued, indicating a potential buy opportunity. The company's positive future outlook and expected earnings increase aren't fully reflected in the current share price. Consider the company's financial health as well.
Despite the good rate of top-line growth at Tandem Diabetes Care, the severe share price drop indicates the company's losses might be larger than expected. Given the stock's past poor performance, there may be unresolved challenges the company is facing.
Read more